GLP-1 brand names - Ozempic, Wegovy, Mounjaro, Zepbound - have become cultural shorthand for weight loss. Every telehealth weight-loss clinic, med spa weight-loss division, and bariatric practice uses them in marketing. Most of that marketing is in some combination of FDA prescription-drug advertising violation and FTC substantiation violation, often with a compounded-drug-equivalency problem layered on top. This post is the full playbook for what the rules actually require and how to market GLP-1 services compliantly.
The issue has three simultaneous layers: (1) Ozempic and Mounjaro are approved for type 2 diabetes, not weight loss; Wegovy and Zepbound are the weight-loss indications; (2) brand-name prescription drug advertising has specific format requirements most clinic marketing does not meet; and (3) compounded GLP-1 marketed as equivalent to brand-name products is its own enforcement category. Getting the marketing right requires handling all three layers.
The labeling reality
Understanding which drug is approved for what matters for every brand-name claim:
- Ozempic (semaglutide). FDA-approved for type 2 diabetes. Not approved for weight loss. Marketing Ozempic specifically as a weight-loss drug is off-label promotion.
- Wegovy (semaglutide, higher dose).FDA-approved for chronic weight management in specific patient populations. The brand name for semaglutide’s weight-loss indication.
- Mounjaro (tirzepatide). FDA-approved for type 2 diabetes. Not approved for weight loss. Marketing Mounjaro specifically as a weight-loss drug is off-label promotion.
- Zepbound (tirzepatide, weight-loss indication).FDA-approved for chronic weight management. The brand name for tirzepatide’s weight-loss indication.
- Compounded semaglutide/tirzepatide. Not FDA-approved - compounded preparations are distinct products prepared by licensed compounding pharmacies. Their regulatory status changes with FDA-declared shortage status and is a complex regulatory picture.
The three-layer exposure model
Layer 1: Off-label indication promotion
Marketing Ozempic or Mounjaro as weight-loss drugs - when their FDA-approved indications are type 2 diabetes - is off-label promotion. Off-label use is generally legal (prescribing outside label is a standard medical practice freedom); off-label marketing is not. The distinction matters and trips up most clinic marketing because the clinical practice (prescribing off-label) is fine while the marketing practice (advertising off-label) is not.
Layer 2: Prescription drug advertising format
Any direct-to-consumer advertising of a prescription drug requires fair balance - risk information presented with equal prominence to benefit information. A typical clinic landing page showing dramatic weight-loss testimonials without corresponding risk information fails this structural requirement.
Layer 3: Compounded-drug equivalency claims
Marketing compounded semaglutide or tirzepatide as equivalent to brand-name products - “same as Ozempic,” “identical active ingredient as Wegovy” - is its own FDA enforcement category. Compounded drugs are legally distinct products and marketing them as equivalents to approved drugs misrepresents the regulatory distinction.
The specific problem patterns
Pattern 1: “Get Ozempic for weight loss”
“Get Ozempic for weight loss - now accepting new patients.”
“Medically supervised weight management with GLP-1 medications - we assess candidacy for approved weight-loss indications and prescribe the appropriate product for each patient.”
Why: Marketing Ozempic specifically as a weight-loss product is off-label promotion since Ozempic's approved indication is type 2 diabetes. The compliant version uses generic medication-class language.
Pattern 2: Compounded-equivalency marketing
“Our compounded semaglutide - the same as Ozempic at a fraction of the price.”
“Our compounded semaglutide - a distinct medication prepared by a licensed compounding pharmacy. We offer this option for patients for whom it is clinically appropriate; candidacy discussed at consultation.”
Why: 'Same as Ozempic' misrepresents the regulatory distinction between approved and compounded products - a specific FDA enforcement target.
Pattern 3: Benefit-only landing pages
“Lose up to 20% of your body weight with our GLP-1 program. Life-changing results. Join thousands of happy patients.”
“Clinical studies of GLP-1 class medications have shown average weight loss of 12%-21% of body weight over 12-18 months in patients who complete the full protocol. Common side effects include nausea, constipation, and GI discomfort. Serious but rare side effects include [list]. Our medical team reviews candidacy, contraindications, and treatment goals at your consultation.”
Why: The compliant version includes fair balance - benefits and risks with comparable prominence - plus substantiation-meeting language for the weight-loss numbers.
Pattern 4: Celebrity/influencer endorsement without disclosure
“[Celebrity] lost 40 pounds on our program - you can too!”
“[Remove entirely unless documented paid endorser with FTC-compliant disclosure of the material connection directly in the post.]”
Why: Celebrity endorsements require FTC material-connection disclosure in the post itself - not in a linked bio, not in fine print. Most clinic celebrity marketing does not meet this.
Pattern 5: “No side effects” or safety absolutes
“Our protocol - effective weight loss with no side effects.”
“Most patients tolerate GLP-1 medications well. Common side effects include nausea, constipation, and GI discomfort, which typically subside with dose titration. Less common but serious side effects exist and are discussed during consultation.”
Why: GLP-1 medications have well-characterized side effect profiles and boxed warnings. 'No side effects' is unsubstantiable and directly contradicts prescribing information.
The compliant playbook
Step 1: Generic medication-class language for top-of-funnel
Ad copy, social media captions, and top-of-funnel landing pages should use generic language - “GLP-1 medications,” “weight-loss injectables,” “medically supervised weight management with modern pharmaceutical options.” This preserves marketing message while avoiding brand-specific exposure.
Step 2: Brand names in informational contexts only
Mention specific brand names in FAQ pages, educational content, and in-consultation discussion. Patient-facing education can explain “we prescribe Wegovy (semaglutide, FDA-approved for chronic weight management in specific populations) and Zepbound (tirzepatide, FDA-approved for chronic weight management) as clinically appropriate; we also offer compounded preparations as a separate option.” This is informative without being promotional.
Step 3: Fair balance on medication pages
Any page describing a specific medication should include risk information with comparable prominence to benefit information. Boxed warnings, common side effects, serious but rare side effects, contraindications, and patient-selection criteria all belong on these pages - not hidden in a linked consent form.
Step 4: Substantiation for outcome numbers
Specific weight-loss numbers require substantiation. The approach that works: cite the underlying clinical trials on the medication class rather than claiming outcome numbers from your own practice. “The STEP-1 trial of semaglutide in patients with obesity (Wilding et al., NEJM 2021) showed average weight loss of approximately 15% of body weight at 68 weeks” is cited, substantiable, and persuasive.
Step 5: Compounded framing that acknowledges the distinction
Compounded preparations can be discussed - they just need to be discussed accurately. “Compounded semaglutide is a distinct medication prepared by a licensed compounding pharmacy under our medical team’s prescriptions. It is not an FDA-approved product and is not the same as Wegovy or Ozempic in regulatory terms; clinically, our team evaluates whether it is appropriate for each patient.”
Step 6: Consultation-forward conversion
Drive conversion to consultation rather than to specific medication selection. “Book a consultation to discuss your weight-loss goals, medical history, and which treatment options - including GLP-1 medications if appropriate - may be right for you.”
Telehealth-specific considerations
Telehealth weight-loss practices have additional compliance layers beyond in-person practices:
- State licensure disclosure. Patients need to know in what states your prescribers are licensed. Marketing to patients in states where your providers are not licensed is a state AG enforcement pattern.
- Clinical evaluation framing.Marketing that minimizes the clinical evaluation step (“script in 24 hours,” “skip the doctor visit”) has drawn state medical board attention. The evaluation step should be framed as genuine medical assessment.
- Pricing transparency. State AG enforcement on telehealth weight-loss pricing has targeted advertised rates that do not include add-ons, lab fees, or medication costs. Clear pricing disclosure is an AG-attention area.
Frequently asked questions
Can I use Ozempic’s brand name at all?
Yes, in informational contexts. FAQs, educational content, consent forms, and in-consultation discussion can all appropriately reference brand names. The issue is promotional contexts - ads, social captions, landing page headlines, discount promotions - where brand names trigger the advertising rules.
What if I only prescribe Wegovy, not Ozempic?
Marketing Wegovy for its approved indication (chronic weight management in specific patient populations) does not carry the off-label exposure Ozempic-for-weight-loss marketing does. You still need to meet prescription-drug advertising format rules (fair balance, specific indication disclosure, etc.), but the off-label layer is removed.
Can compounded-equivalency be disclosed enough to be compliant?
Not to the extent some clinics would like. The problem with “same as Ozempic” language is not a disclosure gap - it’s a factual misrepresentation. Compounded products are regulatorily distinct. No amount of fine print cures that. The compliant path is to describe compounded products accurately as distinct preparations.
What about using manufacturer-provided marketing materials?
Manufacturers don’t generally provide direct-to-consumer marketing materials for clinics to use on their own channels (they run their own DTC advertising). When manufacturers do provide clinician-facing or patient-education materials, use them as-provided. Modifying them introduces the standard compliance issues.
How strict is fair balance on landing pages?
Strict enough that most current clinic landing pages fail. Fair balance requires comparable prominence - not comparable word count, specifically, but similar visual weight, placement, and visibility. Risk information in a collapsed accordion while benefits are in the hero section does not meet the standard.
Is this all going to change when the GLP-1 shortage ends?
The shortage status affects the specific rules around compounded preparations but does not change the brand-advertising or fair-balance rules for FDA-approved products. Expect the compliance landscape for weight loss marketing to remain active regardless of shortage status.